Stock Track | Evolus Plunges 5% Despite Upbeat Earnings on Filler Launch Costs

Stock Track

Mar 05, 2025

Evolus Inc. (EOLS) stock plummeted 5.26% in pre-market trading on Wednesday, despite the company reporting strong Q4 and full-year 2024 financial results that exceeded expectations. The selling pressure likely stems from near-term costs associated with launching the company's new hyaluronic acid filler products.

For the fourth quarter, Evolus delivered global net revenue of $79 million, up 30% year-over-year, driven by continued strong growth of its Jeuveau neurotoxin product line. Evolus achieved non-GAAP operating profitability of $6.7 million in Q4, a significant milestone marking its first-ever quarterly profit.

Full-year 2024 revenue grew 32% to $266.3 million, at the high end of the company's guidance range. Evolus also reported full-year non-GAAP operating profitability, one year ahead of its stated goal. Its neurotoxin product captured around 14% market share in the US by the end of 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1113676313"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113676313\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113676313?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113676313","market":"us","top_or_hot":-1,"title":"Stock Track | Evolus Plunges 5% Despite Upbeat Earnings on Filler Launch Costs","media":"Stock Track","content":"<p>Evolus Inc. (EOLS) stock plummeted 5.26% in pre-market trading on Wednesday, despite the company reporting strong Q4 and full-year 2024 financial results that exceeded expectations. The selling pressure likely stems from near-term costs associated with launching the company's new hyaluronic acid filler products.</p>\n\n<p>For the fourth quarter, Evolus delivered global net revenue of $79 million, up 30% year-over-year, driven by continued strong growth of its Jeuveau neurotoxin product line. Evolus achieved non-GAAP operating profitability of $6.7 million in Q4, a significant milestone marking its first-ever quarterly profit.</p>\n\n<p>Full-year 2024 revenue grew 32% to $266.3 million, at the high end of the company's guidance range. Evolus also reported full-year non-GAAP operating profitability, one year ahead of its stated goal. Its neurotoxin product captured around 14% market share in the US by the end of 2024.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Evolus Plunges 5% Despite Upbeat Earnings on Filler Launch Costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Evolus Plunges 5% Despite Upbeat Earnings on Filler Launch Costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-05 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Evolus Inc. (EOLS) stock plummeted 5.26% in pre-market trading on Wednesday, despite the company reporting strong Q4 and full-year 2024 financial results that exceeded expectations. The selling pressure likely stems from near-term costs associated with launching the company's new hyaluronic acid filler products.</p>\n\n<p>For the fourth quarter, Evolus delivered global net revenue of $79 million, up 30% year-over-year, driven by continued strong growth of its Jeuveau neurotoxin product line. Evolus achieved non-GAAP operating profitability of $6.7 million in Q4, a significant milestone marking its first-ever quarterly profit.</p>\n\n<p>Full-year 2024 revenue grew 32% to $266.3 million, at the high end of the company's guidance range. Evolus also reported full-year non-GAAP operating profitability, one year ahead of its stated goal. Its neurotoxin product captured around 14% market share in the US by the end of 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EOLS","symbol_name":"Evolus Inc.","start_time":0,"source_url":"","article_id":"1113676313","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113676313","pubTimestamp":1741185520,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Evolus Inc.  stock plummeted 5.26% in pre-market trading on Wednesday, despite the company reporting strong Q4 and full-year 2024 financial results that exceeded expectations. The selling pressure likely stems from near-term costs associated with launching the company's new hyaluronic acid filler products.For the fourth quarter, Evolus delivered global net revenue of $79 million, up 30% year-over-year, driven by continued strong growth of its Jeuveau neurotoxin product line. Evolus achieved non-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EOLS":"Evolus Inc."},"translate_title":"尽管填料发布成本盈利乐观，但Evolus股价仍暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":1},"content_text":"Evolus Inc. (EOLS) stock plummeted 5.26% in pre-market trading on Wednesday, despite the company reporting strong Q4 and full-year 2024 financial results that exceeded expectations. The selling pressure likely stems from near-term costs associated with launching the company's new hyaluronic acid filler products.\nFor the fourth quarter, Evolus delivered global net revenue of $79 million, up 30% year-over-year, driven by continued strong growth of its Jeuveau neurotoxin product line. Evolus achieved non-GAAP operating profitability of $6.7 million in Q4, a significant milestone marking its first-ever quarterly profit.\nFull-year 2024 revenue grew 32% to $266.3 million, at the high end of the company's guidance range. Evolus also reported full-year non-GAAP operating profitability, one year ahead of its stated goal. Its neurotoxin product captured around 14% market share in the US by the end of 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}